PBH Prestige Consumer Healthcare Inc.
XNYS 49.92 DelayedStock quote, options chain, IV rank, technicals, AI analysis, and institutional ownership. Iron condor setups Expected move IV rank history Fibonacci levels Insider trading
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
PBH
$49.92
—
Key stats
$49.92
- 52-Week Range
- $42.62 – $71.07
- YTD
- -18.46%
- IV Rank (30D)
- 21.82
- Straddle Price
- $5.05
- P/C Vol Ratio
- 0.05
- Market Cap
- $2.3B
- Open
- $49.48
- Day Range
- $49.28 – $50.27
- Volume
- 580,660
- Prev Close
- $49.20
Fair Value
MODEL: LONG
A blended fair-value estimate combining up to six valuation methods. Each method is weighted by how well it fits the company — DCF down-weights for unprofitable names; DDM only fires for steady dividend payers; comparables down-weight when peer multiples disagree.
- DCF (quality-aware) — projects free cash flow with a horizon that scales to business quality. True compounders (quality 6/6) get 10 years explicit + 10 years fade before terminal; cyclical/struggling names (quality 0-1) get a 5-year terminal cliff. Quality is scored from ROE, gross margin, growth, FCF margin, debt load, and FCF consistency — the same factors that drive market premium for compounders.
- Market-Implied Growth (in Model Inputs) — reverse-DCF that answers "what growth rate is the market pricing in?". Lets you sanity-check the deviation: if implied growth is plausible for the business, the model's bearish flag may be wrong; if implausible, the market may be over-extrapolating.
- DDM (Gordon Growth Dividend Model) — values the stream of future dividends. Only used when trailing yield ≥ 2% and dividend payments are stable — below that the dividend is a token payout and Gordon (which values only the dividend stream) systematically underprices growth names, so those route to DCF + comparables + market anchor instead.
- P/E, EV/EBITDA, P/B, P/S — applies the peer-group median multiple to this company's per-share metric. Peers come from the same set as the "Related symbols" card. Earnings/sales metrics are forward-tilted by the company's recent revenue growth (capped at 25%) so they're comparable to peers' growth-embedded multiples — mimics how analysts use NTM rather than TTM. Per-multiple weights are biased by company quality (e.g. P/B down-weighted for asset-light tech).
- Market Anchor (SMA50) — the 50-day moving average, weighted by recent trading-range stability (tighter Bollinger bands → higher weight). Captures information fundamentals miss (forward consensus, sentiment, supply/demand) — but only when recent trading is steady enough that the market has converged on a view. During wild breakouts or breakdowns the anchor's weight collapses.
- Options Expected (B-L 30d) — the risk-neutral expected stock price at 30-day options expiration, derived from the full implied-volatility surface via Breeden-Litzenberger (second derivative of call price wrt strike → implied PDF, then E[S_T]). Forward-looking, captures all options-implied information (smile, skew, term structure) in one number. Weighted by chain liquidity. SP500-only at present (pre-computed daily). Backtest evidence: adds modest alpha across most bucket × holding combos.
- Blended value — weighted average. Confidence reflects how many methods fired and how tight peer dispersion is.
- Deviation pill — green when blended FV ≥ 10% above current price (undervalued); red when ≥ 10% below; grey otherwise.
| 10-yr Treasury (rf) | 5.21% |
| Beta vs SPY | 0.60 |
| Cost of Equity (CAPM) | 8.22% (VRP-adj) |
| WACC | 6.71% |
| Volatility Risk Premium | +30.7pp (IV − HV30) |
| Effective Tax Rate | 26.6% |
| Rev. Growth (YoY, DCF input) | -3.1% |
| DCF Horizon | 10 years explicit + fade |
| Free Cash Flow (TTM) | $0.2B |
| Return on Equity (TTM) | 9.0% |
| Book / Price | 80.5% — banking bias active (P/B is primary) |
| Gross Margin (TTM) | 53.5% |
| FCF Margin (TTM) | 21.3% |
| Debt / Equity | 1.06 |
| Quality Score | 3/6 — normal (10y DCF) |
| Market-Implied Growth | -1.9% (reverse-DCF on current price) |
| SMA 50 | $49.30 (Market Anchor value) |
| SMA 20 / Bollinger Mid | $46.90 |
| Bollinger Width / SMA20 | 24.0% (drives anchor stability) |
| Net Debt | $1.9B |
| Market Cap | $2B |
Peers used for multiples: ABT, NVS, PFE
(SIC-code peers; ETF co-membership was sector-incoherent)
60-Day Conviction
90%
20-Day Fair Value
≈ by Nov 16, 2026
$50.64
α +1.4%
rank 74%
conviction
75%
40-Day Fair Value
≈ by Dec 15, 2026
$51.80
α +3.8%
rank 78%
conviction
91%
60-Day Fair Value
≈ by Jan 13, 2027
$51.76
α +3.7%
rank 70%
conviction
90%
| Method | Implied Price | Weight | Detail |
|---|---|---|---|
| DCF | $42.95 | 29% | |
| DDM (Gordon) | n/a | 0% | |
| Peer P/E | $137.20 | 9% | median 38.4× · 3 peers |
| Peer EV/EBITDA | $86.99 | 9% | median 19.1× · 3 peers |
| Peer P/B | $138.16 | 9% | median 3.5× · 3 peers |
| Peer P/S | $87.17 | 9% | median 3.8× · 3 peers |
| Market Anchor (SMA50) | $49.30 | 36% | stability 61% (BB-width) |
| Options Expected (B-L 30d) | $48.08 | 0% | 7 strikes · skew -0.51 |
As of 2026-10-16 · updated
Related
About
- Industry (SIC)
- PHARMACEUTICAL PREPARATIONS (2834) · industry map
- Exchange
- XNYS
- Market Cap
- $2.3B
- Employees
- 890
- List Date
- 2005-02-10
- CIK
- 0001295947
- Next Earnings
- 2026-11-05 (Pre-Market)
- EPS Forecast
- $1.06 (4 est.)
- Headquarters
- Tarrytown, NY
- Homepage
- https://www.prestigebrands.com
Prestige Consumer Healthcare is one of the largest pure-play over-the-counter healthcare providers. It has a diverse portfolio composed of leading brands in niche consumer health categories. Prestige's key brands include Clear Eyes (redness relief), Dramamine (motion sickness relief), Monistat (vaginal anti-fungal), and Summer's Eve (feminine hygiene), and many of its brands enjoy category leadership and recommendations from medical professionals. The firm mainly plays in North America where it generates roughly 85% of its total revenue, and the remaining sales come from Australia, New Zealand…
Summary
—
composite
—
No summary data available for this symbol yet.
Each spoke is this symbol's rank within its sector (0–100; the dotted ring marks the sector median at 50). Higher is more constructive for a long. One spoke — News sentiment — is an absolute reading, not a sector rank. Grayed spokes have no data. A fuller shape is a summary, not a recommendation.
Chart
Seasonality
| Month | '21 | '22 | '23 | '24 | '25 | '26 | Avg |
|---|---|---|---|---|---|---|---|
| Jan | 10.62% | -6.88% | 3.61% | -0.73% | -1.22% | 5.31% | 1.78% |
| Feb | 2.01% | 5.14% | -8.97% | 11.27% | 12.52% | 5.90% | 4.64% |
| Mar | 4.26% | -11.19% | 3.45% | 3.46% | 0.84% | -13.51% | -2.11% |
| Apr | 1.14% | 3.00% | -3.04% | 0.11% | -5.25% | -2.36% | -1.07% |
| May | 12.50% | 2.48% | -8.37% | -9.58% | 4.18% | -13.72% | -2.08% |
| Jun | 4.35% | 5.45% | 4.81% | 7.66% | -6.60% | 2.87% | 3.09% |
| Jul | -0.49% | 1.23% | 10.19% | 4.52% | -7.93% | 4.19% | 1.95% |
| Aug | 8.80% | -17.24% | -10.77% | 5.80% | -7.70% | -0.27% | -3.56% |
| Sep | -2.21% | -2.75% | -2.02% | -2.69% | -6.17% | -12.86% | -4.78% |
| Oct | 8.27% | 9.51% | 3.72% | 4.12% | -4.36% | 11.50%* | 5.46% |
| Nov | -7.69% | 10.88% | -3.63% | 14.48% | -1.70% | -- | 2.47% |
| Dec | 6.20% | -0.33% | 4.45% | -8.12% | 2.94% | -- | 1.03% |
| Total | 56.98% | -4.57% | -8.62% | 31.25% | -20.26% | -15.61% | 6.53% |
Technical Indicators
Quick-reference for reading the values below. Indicators combine to confirm a view — no single one is a trade signal on its own.
Trend Indicators
- SMA 20 / 50 / 200 — price above = uptrend, below = downtrend. SMA 50 crossing SMA 200 is the golden/death cross.
- EMA 12 / 26 — faster-reacting averages; 12 above 26 is short-term bullish.
- MACD — bullish when MACD > signal (green badge), bearish when below. Divergence from price often precedes reversals.
- ADX (14) — trend strength regardless of direction. <20 range, 20–25 weak trend, 25–50 trend, >50 strong trend.
- +DI / −DI — +DI > −DI favors bulls; the reverse favors bears. Read alongside ADX.
Momentum Oscillators
- RSI (14) — <30 oversold, >70 overbought. 40–60 is neutral; trending names can stay extreme.
- Stochastic %K / %D — <20 oversold, >80 overbought. %K crossing %D is an early momentum signal.
- Williams %R — inverted scale: <−80 oversold, >−20 overbought.
Oscillators work best in range-bound markets; in strong trends they give premature reversal signals.
Volume & Volatility
- Bollinger Bands — price at upper band = overbought, lower = oversold. Narrow bands (squeeze) often precede expansion.
- OBV — cumulative volume; rising OBV confirms uptrend, falling OBV confirms downtrend. Divergence from price is a warning.
- Vol SMA 20 / Vol ROC — today's volume vs. 20-day average. Positive ROC with price move = conviction.
- ATR / True Range — average daily $ move; sizing and stop-loss reference.
- HV 20 / 30 / 60 — realized (historical) volatility. Compare to IV on the options cards: IV > HV = rich premium.
Confluence matters: trend + momentum + volume agreeing carries far more weight than any single indicator. For how these feed the spread scanner score, see the algorithm docs →
Trend Indicators
SMA 20: $47.15
SMA 50: $49.21
SMA 200: $54.83
Current: $49.92
EMA 12: $48.15
EMA 26: $47.99
MACD: 0.1599 | Signal: 0.5224
BEARISH
ADX (14): 20.69
WEAK TREND
+DI: 27.49
−DI: 17.22
Momentum Oscillators
RSI (14): 60.44
NEUTRAL
Stoch %K: 77.44
Stoch %D: 77.20
Williams %R: -14.74
Volume & Volatility
BB Upper: $49.95
BB Lower: $44.36
NEUTRAL
OBV: -1,084,428
Vol SMA 20: 563,706
Vol ROC: 6.76%
ATR: $1.44
True Range: $1.07
HV 20: 29.2%
HV 30: 32.8%
HV 60: 32.1%
Data Summary
Data Points: 500
Last Updated:
Date Range: 2024-10-18T00:00:00 – 2026-10-16T00:00:00
AI Analysis
COMPREHENSIVE STOCK ANALYSIS REPORT
Symbol: PBH (Prestige Consumer Healthcare Inc.)
EXECUTIVE SUMMARY
Overall Assessment: NEUTRAL with Confidence Level: 6/10
Prestige Consumer Healthcare presents a conflicted technical and sentiment picture. The stock is trading near all-time highs ($49.92, just 0.06% below the upper Bollinger Band at $49.95) with positive news sentiment dominated by value-focused narratives, yet momentum indicators reveal deteriorating conditions underneath. The bearish MACD crossover (-0.36 histogram), weakening trend strength (ADX 20.69), and negative OBV (-1,084,429) suggest weakening accumulation despite the recent price advance. The unusual negative beta (-0.03) provides defensive characteristics, but this also means the stock lacks the market tailwind that could validate a sustained breakout.
Key Drivers:
- Recent acquisition of LaCorium Health (July 2026) positioning for portfolio expansion
- Consistent value stock positioning in recent analyst commentary
- Technical exhaustion near resistance levels with weak volume support
Primary Risks:
- Bearish momentum divergence at price highs
- Negative OBV indicating distribution, not accumulation
- Weak trend strength suggests price advance lacks conviction
- Upcoming earnings catalyst (Nov 5, 2026) could trigger volatility
Investment Thesis: PBH has attracted value-focused investors and completed strategic M&A activity, but technical deterioration suggests current price levels may represent distribution rather than accumulation. The negative OBV and bearish MACD at price highs create asymmetric risk, with downside protection limited until the stock reaches the SMA 50 support level.
Recent News Sentiment Impact: Positive sentiment (4 positive, 1 neutral in last 15 months) reflects value-oriented positioning and strategic M&A completion. However, the most recent headline (Oct 15, 2026) shifts tone from "buy" to "retain," which may explain the lack of sustained bullish momentum despite positive news. News tailwinds appear to be fading just as technical momentum weakens.
TECHNICAL ANALYSIS
Trend Direction
Short-term (1-4 weeks): BEARISH DIVERGENCE
- Price: $49.92 (near 20-day highs, +5.9% above SMA 20 of $47.15)
- The stock has rallied significantly above the 20-day MA, yet MACD has turned bearish and RSI remains neutral at 60.44
- This suggests the short-term rally is losing momentum
- ADX at 20.69 indicates a weak trend—the +DI (27.49) exceeds -DI (17.22), but ADX below 25 means neither directional force is strong
Medium-term (1-3 months): MIXED
- Price above SMA 50 ($49.21) provides uptrend structure
- However, price remains significantly below the SMA 200 ($54.83), which is 9.9% above current price
- The stock is in a correction within a longer-term downtrend
- Medium-term bias neutral-to-bearish until price recaptures the 200-day MA
Long-term (3-12 months): BEARISH
- Price is $4.91 (8.9%) below the 200-day MA
- SMA 50 ($49.21) is below SMA 200 ($54.83), confirming a bearish crossover structure
- The stock remains in a confirmed downtrend from longer-term perspective
- Negative alpha (-0.16) suggests underperformance relative to risk taken
Support/Resistance Levels
| Level | Type | Distance | Significance | |-------|------|----------|--------------| | $49.95 | Resistance | +0.06 | Upper Bollinger Band — price bumping against upper resistance | | $50.50 | Resistance | +$1.03 | Recent 52-week consideration | | $49.21 | Support | -$0.71 | SMA 50 — intermediate uptrend support | | $47.15 | Support | -$2.77 | SMA 20 — short-term support, BB midline | | $44.36 | Support | -$5.56 | Lower Bollinger Band — strong technical support | | $54.83 | Major Resistance | +$4.91 | SMA 200 — major trend reversal point |
Critical Observation: Price is pinned against the upper Bollinger Band with width at 11.85 (moderate expansion). Typical mean-reversion patterns suggest increased probability of pullback toward the middle band ($47.15) in the near term.
Momentum Signals
RSI (14): 60.44 — NEUTRAL
- RSI sits in the neutral zone (30-70 range), neither overbought nor oversold
- No extreme momentum in either direction
- RSI reading of 60.44 is approaching the midpoint (50), suggesting momentum may be cooling
- Combined with bearish MACD, this suggests momentum is shifting from positive to negative
MACD: 0.16 / Signal: 0.52 / Histogram: -0.36 — BEARISH CROSSOVER
- Critical Signal: MACD (0.16) is trading below its signal line (0.52), creating a bearish crossover
- Histogram at -0.36 (negative) confirms the crossover and deteriorating momentum
- This is the most concerning technical signal on the chart
- Even though price remains elevated, the MACD suggests momentum peaked and is reversing
- This divergence (price at highs, MACD turning down) is a classic distribution pattern
Stochastic Oscillators: %K 77.44 / %D 77.20 — OVERBOUGHT
- Both %K and %D are above 70, indicating overbought conditions
- %K and %D are nearly equal, suggesting momentum has peaked and may be reversing
- Red Flag: Overbought stochastics combined with bearish MACD crossover increases probability of pullback
- Williams %R at -14.74 (above -20) also confirms overbought territory
Bollinger Bands Position: NEUTRAL (but at resistance)
- Upper Band: $49.95 (price touching)
- Middle Band: $47.15
- Lower Band: $44.36
- Width: 11.85
Interpretation:
- Price is pinned at the upper band, typically associated with overbought conditions
- Band width of 11.85 shows moderate volatility expansion (not extreme compression)
- The gap between price ($49.92) and middle band ($47.15) is 5.9%, suggesting price is extended
- Mean reversion probability increases when price touches bands without strong directional bias
- Negative OBV (detailed below) suggests this may be exhaustion, not accumulation
Volume Analysis
Volume SMA 20: 563,706
- Current trading volume appears low relative to historical 20-day average
- Volume Rate of Change: +6.76% (slight increase, but not substantial)
- Concern: Recent rally has occurred on below-average volume, suggesting lack of conviction
On-Balance Volume (OBV): -1,084,429 — CRITICAL BEARISH DIVERGENCE
- This is the most damaging technical signal
- Negative OBV means cumulative selling pressure exceeds buying pressure
- OBV divergence: Price is at 52-week highs, but OBV is deeply negative
- This pattern indicates institutional or smart money distribution
- The stock is being sold into strength, not bought on dips
- This explains why the rally lacks conviction despite positive news
Volume Rate of Change: +6.76% — MARGINAL
- Slight increase in volume, but insufficient to confirm bullish conviction
- Lacks the 20-30%+ volume expansion needed to validate a breakout above resistance
Institutional Interest Signal:
- Negative OBV strongly suggests institutional selling/distribution
- Combined with positive news and flat-to-negative momentum, this points to "sell the news" activity
- Institutions may have accumulated during weakness and are exiting ahead of the Nov 5 earnings
NEWS & SENTIMENT ANALYSIS
Recent Headlines Summary (Last 15 Months)
| Date | Headline | Sentiment | Theme | |------|----------|-----------|-------| | Oct 15, 2026 | "Is it Apt to Retain PBH in Your Portfolio?" | NEUTRAL | Tone Shift: Changed from "buy" to "retain" | | Oct 1, 2026 | "Best Value Stocks to Buy
Generated
News
All PBH news →
Earnings History
10 of 14 under expected move
Avg Expected Move
7.57%
Avg Actual Move
4.22%
| Earnings Date | Timing | Expected Move | Actual Move | Ratio | Outcome |
|---|---|---|---|---|---|
| 2021-02-04 | Pre-Market | 8.67% | 1.90% | 0.22x | Within |
| 2023-05-04 | Pre-Market | 10.38% | 1.26% | 0.12x | Within |
| 2023-08-03 | Pre-Market | 4.70% | 0.94% | 0.20x | Within |
| 2023-11-02 | Pre-Market | 5.93% | 0.57% | 0.10x | Within |
| 2024-02-08 | Pre-Market | 7.60% | 9.36% | 1.23x | Exceeded |
| 2024-08-08 | After-Close | 7.11% | 0.88% | 0.12x | Within |
| 2024-11-07 | Pre-Market | 7.50% | 3.16% | 0.42x | Within |
| 2025-02-06 | Pre-Market | 6.44% | 14.78% | 2.30x | Exceeded |
| 2025-05-08 | Pre-Market | 6.73% | 6.92% | 1.03x | Exceeded |
| 2025-08-07 | Pre-Market | 6.19% | 10.05% | 1.62x | Exceeded |
| 2025-11-06 | Pre-Market | 8.48% | 2.56% | 0.30x | Within |
| 2026-02-05 | After-Close | 7.21% | 1.19% | 0.17x | Within |
| 2026-05-13 | Pre-Market | 9.67% | 2.78% | 0.29x | Within |
| 2026-08-06 | Pre-Market | 9.34% | 2.74% | 0.29x | Within |
Earnings calendar: this week’s reports with expected vs actual moves →
PBH Options Activity & IV Rank
PBH IV rank history, 52-week IV rank and IV percentile →
Volatility Metrics
Current IV: 41.2%
7-DTE IV: —
Expected Move: $5.05
7-DTE Move: $2.65
Days to Exp: 35 (2026-11-20)
Options Flow
Call Volume: 40
Put Volume: 2
P/C Volume: 0.05
BULLISH
Call OI: 41
Put OI: 2
P/C OI: 0.049
Total OI: 43
ATM Options Pricing
ATM Call: $2.58
ATM Put: $2.48
Call %: 5.2%
Put %: 5.0%
Chain Summary
Chain Volume: 146
Chain OI: 935
Last Updated: 10/16/2026
Spread Scanner GPU
Each spread is ranked by a composite score built in three stages. Full documentation →
Stage 1 — Base Score (GPU scanner)
score = P(profit) × (credit / spread_width)
P(profit) from short leg delta (1 − |delta|), penalised above 85%. Credit uses mid-price to handle illiquid chains fairly.
Stage 2 — Skew Adjustment (±25% cap)
RR and BF (30-delta) from the persisted per-symbol skew snapshot — wing strikes picked by real greeks.delta, not a moneyness proxy. Put skew boosts bull puts, penalises bear calls. High butterfly boosts iron condors. Calendars are skew-neutral.
Stage 3 — Technical Overlay (±50% cap, 5 groups)
Group 1 · Directional Bias (±0.25)
- RSI <40 bullish / >60 bearish
- MACD crossover + histogram trend
- Price vs SMA 50 & SMA 200
Group 2 · Momentum (±0.10)
- Stochastic %K <20 / >80
- Williams %R <−80 / >−20
Group 3 · Volatility (up to −0.25 / +0.15)
- Blended ATR + straddle expected-move penalty
- Bollinger Band signal (+ counter-trend penalty)
- BB width — vol contraction boost for ICs
Group 4 · IV Regime (±0.15)
- IV rank ≥ 75 → strong boost for credit spreads
- IV rank < 25 → penalty (selling cheap vol)
Group 5 · Liquidity (penalty up to −0.10)
- Min open interest across all legs
- OI < 100 → −0.10 · OI < 500 → −0.05
score = base_score × skew_multiplier × tech_multiplier
Both multipliers are shown per spread. Beta is informational only — ATR already captures realized vol. Full algorithm documentation →
Enter a ticker to scan for optimal spread opportunities.
Evaluates all bull put, bear call, iron condor, and calendar spread combinations using GPU-accelerated analysis.
Dealer Positioning
HIGH γ vs HISTORY
Estimated net dealer gamma is at the 99th percentile of this name's own daily history, near the high end of its range. This describes current positioning; it is not a forecast or a trading signal.
Gamma percentile
99%
vs own history
GEX tilt
+0.83
OI-weighted, today
Vanna tilt
+1.00
δ-sensitivity to IV
Charm tilt
-1.00
δ-decay vs time
Vanna tilt +1.00: the estimated dealer exposure leans positive, so the modeled hedge would shift noticeably if implied volatility changed.
Charm tilt -1.00: the estimated dealer exposure leans negative, so the modeled hedge would shift noticeably as time passes and options approach expiry.
? What is this?
· 3 ATM contracts, 1k total OI
Net dealer gamma is an estimate of the aggregate gamma held by options market makers across this name's option chain, weighted by open interest. Dealer positions aren't public, so it uses a standard simplifying assumption: dealers are treated as long the calls and short the puts that are open. Actual dealer books can differ.
Gamma percentile ranks today's estimate against this name's own daily history, from 0% (the lowest reading on record) to 100% (the highest). Raw gamma scales with how much open interest a chain carries, so it isn't comparable across names; the percentile is. The badge marks the bottom 20% as low and the top 20% as high.
Tilts run from −1 to +1 and show how lopsided the estimated dealer exposure is. GEX tilt compares call gamma with put gamma. Vanna tilt describes how the hedge would shift if implied volatility changed, and charm tilt how it would shift with the passage of time.
This card describes estimated positioning and where it sits historically. It is not a forecast of price direction or volatility and not a trading signal. Market-wide view: Dealer positioning screener.
Skew (Wing IV − ATM IV)
DTE:
Wing Δ:
Wing vs ATM
IV(put wing) − IV(ATM), in vol pointsHow much the OTM put trades above (or below) the at-the-money strike. Measures the height of the put-side tail relative to ATM — i.e. how expensive crash insurance is on this name.
- Positive (typical) — wing IV > ATM IV. Standard equity put skew: portfolios bid up crash protection, so OTM puts trade richer than ATM.
- Near zero or negative (unusual) — wing IV ≤ ATM IV. Flat or inverted put side. Common when there's no fear demand, in tightly mean-reverting names, or right after an earnings catalyst clears.
- Percentile vs own 3-yr history: high = wings rich (good time to sell wing premium); low = wings cheap (good time to buy protection).
- Not directional — high or low wings don't predict up or down moves. It's a price tag on tail insurance, not a forecast.
Risk Reversal
IV(call wing) − IV(put wing), equal delta on each sideWhich side of the smile is the market paying up for? Measures the tilt of the surface — call skew vs put skew at matched deltas.
- Negative (typical) — puts richer than calls. Standard equity behavior: hedging demand makes puts carry a premium. Most large-caps sit in the −1 to −5 vol-point range.
- Strongly negative (< −5 pts) — heavy downside hedging, elevated fear, or an upcoming catalyst (earnings, FDA, macro event). Worth flagging.
- Positive — calls richer than puts. Unusual for equities; signals bullish momentum, short-squeeze positioning, or takeover/M&A speculation.
- Near zero — symmetric surface. Market sees roughly equal up/down risk. Rare for large-caps; more common in commodities and FX.
Reading them together
Wing-vs-ATM tells you how expensive the tails are. Risk Reversal tells you which side is favored. Combined:
- High wing percentile + deeply negative RR → strong put bid; stress or major event priced in. Owning protection costs a premium; selling put premium is dangerous.
- Low wing percentile + near-zero RR → complacency; insurance cheap and balanced. Good environment to add cheap downside hedges.
- Positive RR + elevated wings → call-side fear-of-missing-out; common in squeeze setups. Upside calls expensive, downside puts not bid.
14 DTE / 10d
—
—
pts
EXTREME
as of Oct 16 · No data
30 DTE / 10d
—
—
pts
EXTREME
as of Oct 16 · ATM 41.0% / Wing —
Extreme reading.
Historically these have been contrarian — on the small set of observed earnings-day cases, large negative wing-vs-ATM gaps (calls pricing much richer than puts at the same delta) preceded sharp drops in the underlying within 1-12 days. Not financial advice and the dataset is small.
Percentile is the rank of today's reading within ~3 years of this symbol's own history. High percentile = wings are rich relative to history; not a directional signal. Skew is read off the chain in real time, not from CBOE SKEW.
Volatility Surface
Enter a ticker to render the implied volatility surface.
Volatility Smile
Enter a ticker to render the implied volatility smile.
IV Rank (7 DTE)
IV Rank (30 DTE)21.8LowOct 16
Straddle Price (30 DTE)$5.05Oct 16
Beta Analysis
Risk Metrics
Beta: -0.0329
Alpha: -15.64%
Correlation: -0.0129
R-Squared: 0.0%
Stock Volatility: 32.4%
Market Volatility: 12.7%
Analysis Details
Benchmark: SPY
Data Points: 251
Period: 252 trading days
Data Points: 251
Period: 252 trading days
Interpretation:
Negative beta - stock moves opposite to market
Negative beta - stock moves opposite to market
Beta & Alpha Over Time
Notable investors who own PBH
4 of 37 tracked investors
| Investor | Value | Share of their portfolio | Rank | Q/Q shares | Source |
|---|---|---|---|---|---|
| Citadel Hedge fund Ken Griffin | $26.7M | #992 of 6285 | +207.5% | 13F | |
| Bridgewater Associates Hedge fund Ray Dalio | $2.2M | #693 of 997 | new | 13F | |
| Millennium Management Hedge fund Izzy Englander | $2.2M | #2527 of 3716 | -82.1% | 13F | |
| Rockefeller Capital Management Family office Rockefeller family | $260K | #2457 of 4729 | +47.6% | 13F |
Hedge funds, activists, holding companies and family offices we track, from their latest 13F (quarter-end value) and Form 4 filings in the last 3 years. Family offices · all institutions
PBH Institutional Ownership (13F)
Latest filings — 2026-09-30
? 13F Guide
Diluted shares outstanding: 48,418,750 (as of 2026-06-30)
Institutional managers with $100M+ AUM file Form 13F-HR quarterly, due 45 days after quarter end. Holdings are reported gross at quarter-end market value — they are a snapshot, not a real-time position.
- Shares — long equity positions in this name, aggregated across share classes.
- Calls / Puts — notional value of long call / put exposure where this ticker is the underlying.
- % of Float — holder's reported shares divided by the latest diluted shares outstanding. Sums above 100% indicate large custodian / prime broker positions where the same shares are reported by multiple filers.
- Custodian badge — filers with more than 5,000 holdings are typically broker-dealers / custodians reporting customer-held shares, not active managers.
Each filer is counted once at its latest 13F-HR filing. New filings are ingested on a weekly cadence.
1 filers$4.73K notional
| # | Filer | Notional Value | % of Total | Period |
|---|---|---|---|---|
| 1 | Simplex Trading, LLC Custodian | $4.73K | 100.00% | 2026-06-30 |
1 filers$28.36K notional
| # | Filer | Notional Value | % of Total | Period |
|---|---|---|---|---|
| 1 | Simplex Trading, LLC Custodian | $28.36K | 100.00% | 2026-06-30 |
PBH Insider Trading (Form 4)
Latest: 2026-08-05Form 4 filings — insider beneficial-ownership changes by officers, directors, and 10%+ holders. Filed within 2 business days of transaction.
| Filed | Reporter | Role | Action | Shares | Avg Price | Net $ | Link |
|---|---|---|---|---|---|---|---|
| 2026-08-05 | James DArecca | Director | Award (A) | +2,981 | — | EDGAR | |
| 2026-08-05 | Dawn M. Zier | Director | Award (A) | +2,981 | — | EDGAR | |
| 2026-08-05 | John F. Kelly | Director | Award (A) | +2,981 | — | EDGAR | |
| 2026-08-05 | John E Byom | Director | Award (A) | +2,981 | — | EDGAR | |
| 2026-08-05 | Celeste A. Clark | Director | Award (A) | +2,981 | — | EDGAR | |
| 2026-05-14 | Christine Sacco | CFO & COO | Tax (F) | −1,091 | $55.09 | -$60.1K | EDGAR |
| 2026-05-12 | Jeffrey Zerillo | Senior VP Operations | Sell (S) | −351 | $52.28 | -$18.4K | EDGAR |
| 2026-05-11 | Adel Mekhail | EVP, Marketing & Sales | Tax (F) | −487 | $54.59 | -$26.6K | EDGAR |
| 2026-05-11 | Christine Sacco | CFO & COO | Tax (F) | −991 | $54.59 | -$54.1K | EDGAR |
| 2026-05-11 | Ronald M. Lombardi | Chief Executive Officer | Tax (F) | −2,543 | $54.59 | -$138.8K | EDGAR |
| 2026-05-11 | Jeffrey Zerillo | Senior VP Operations | Mixed | −656 | $54.48 | -$35.7K | EDGAR |
| 2026-05-07 | Ronald M. Lombardi | Chief Executive Officer | Tax (F) | −2,197 | $55.75 | -$122.5K | EDGAR |
| 2026-05-07 | Jeffrey Zerillo | Senior VP Operations | Mixed | −1,514 | $55.14 | -$83.5K | EDGAR |
| 2026-05-07 | Christine Sacco | CFO & COO | Tax (F) | −1,267 | $55.75 | -$70.6K | EDGAR |
| 2026-05-06 | Christine Sacco | CFO & COO | Mixed | +15,550 | $55.31 | -$189.9K | EDGAR |
Codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (described in filing footnote — typically 401(k), trust, inheritance) · W = will/inheritance. Only P / S codes carry directional signal.
PBH Insider Holdings
13 insiders · @ $49.92
Officers, directors, and 10%+ owners who have filed a Form 4 in the past two years, ranked by current disclosed exposure (shares × today's price). Shares are direct + indirect (via trusts / LLCs / spouse). Excludes unvested RSU and option grants — those aren't beneficially owned until vest.
| # | Insider | Role | Shares | Disclosed Exposure | Lifetime OM Net | Filings | Last Filed |
|---|---|---|---|---|---|---|---|
| 1 | Ronald M. Lombardi | Chief Executive Officer | 373,465 | $18.64M | -$20.20M | 61 | 2026-05-11 |
| 2 | Christine Sacco | CFO & COO | 57,374 | $2.86M | -$7.40M | 36 | 2026-05-14 |
| 3 | John E Byom | Director | 54,575 | $2.72M | -$610.1K | 19 | 2026-08-05 |
| 4 | Jeffrey Zerillo | Senior VP Operations | 41,810 | $2.09M | -$246.4K | 28 | 2026-05-12 |
| 5 | Sheila Hopkins | Director | 30,123 | $1.50M | $0 | 11 | 2025-08-06 |
| 6 | William P'Pool | See Remarks | 25,950 | $1.30M | -$4.23M | 34 | 2026-05-06 |
| 7 | Adel Mekhail | EVP, Marketing & Sales | 25,703 | $1.28M | -$4.89M | 25 | 2026-05-11 |
| 8 | Dawn M. Zier | Director | 19,514 | $974.1K | $0 | 9 | 2026-08-05 |
| 9 | Mary Beth Fritz | SVP Quality & Regulatory | 17,051 | $851.2K | -$4.57M | 36 | 2025-05-09 |
| 10 | Celeste A. Clark | Director | 16,511 | $824.2K | $0 | 7 | 2026-08-05 |
Lifetime OM Net = signed sum of open-market buys (P) and sells (S) over their career; excludes grants, tax withholdings, and dispositions to issuer. A large negative number is normal for long-tenured executives — they've sold compensation grants over many years.
PBH Proposed Insider Sales (Form 144)
Latest: 2026-05-11
? Form 144 Guide
Last 30d:
0 filings
· Last 90d:
0 filings
What is Form 144? A notice of intent to sell restricted or control stock under Rule 144. Affiliates (officers, directors, 10%+ owners) and holders of restricted shares must file Form 144 when planning to sell more than 5,000 shares or $50,000 in any 3-month rolling window.
How it relates to Form 4: Form 144 is filed before the trade (up to 90 days in advance); Form 4 is filed within 2 business days after the trade executes. Not every Form 144 results in a sale — the filer may cancel or delay. Look for the corresponding Form 4 on the Insider Activity card to confirm a sale actually happened.
10b5-1 plans: Trades made under a pre-scheduled Rule 10b5-1 plan are not discretionary — they execute automatically on dates set months earlier, regardless of news. High 10b5-1 percentages mean less per-filing signal value, though cumulative selling volume still matters.
"Notice value": Aggregate market value the filer wrote into the Form 144 — i.e. the size of the planned sale, not necessarily the executed dollars. An amended notice (Form 144/A) replaces the original it amends, and cancelled notices are dropped, so neither is double-counted above. A filed value that is clearly inconsistent with the share count at the stock's price (a filer typo) shows as a dash and is left out of the totals.
Source & freshness: Sourced from public Form 144 filings. Refreshed daily; new filings typically appear here the morning after they are filed.
| Filed | Filer | Role | Shares | Notice Value | Planned Sale | Broker | Plan | Link |
|---|---|---|---|---|---|---|---|---|
| 2026-05-11 | Zerillo Jeffrey | Officer | 351 | $18.4K | 2026-05-11 | Fidelity Brokerage Services LLC | 10b5-1 | EDGAR |
| 2026-05-07 | Zerillo Jeffrey | Officer | 305 | $16.6K | 2026-05-07 | Fidelity Brokerage Services LLC | 10b5-1 | EDGAR |
| 2026-05-06 | Zerillo Jeffrey | Officer | 1,207 | $66.4K | 2026-05-06 | Fidelity Brokerage Services LLC | 10b5-1 | EDGAR |
| 2026-05-05 | Zerillo Jeffrey | Officer | 346 | $19.1K | 2026-05-05 | Fidelity Brokerage Services LLC | 10b5-1 | EDGAR |
| 2026-02-11 | Zerillo Jeffrey | Officer | 1,000 | $65.9K | 2026-02-11 | Fidelity Brokerage Services LLC | 10b5-1 | EDGAR |
| 2025-12-01 | Zerillo Jeffrey | Officer | 281 | $16.9K | 2025-12-01 | Fidelity Brokerage Services LLC | 10b5-1 | EDGAR |
| 2025-11-28 | Zerillo Jeffrey | Officer | 719 | $43.1K | 2025-11-28 | Fidelity Brokerage Services LLC | 10b5-1 | EDGAR |
| 2025-11-25 | BYOM JOHN E | Director | 3,000 | $178.1K | 2025-11-25 | Fidelity Brokerage Services LLC | — | EDGAR |
| 2025-03-10 | Fritz Mary Beth | Officer | 1,678 | $151.0K | 2025-03-10 | Fidelity Brokerage Services LLC | 10b5-1 | EDGAR |
| 2025-03-03 | Fritz Mary Beth | Officer | 6,297 | $537.7K | 2025-03-03 | Fidelity Brokerage Services LLC | 10b5-1 | EDGAR |
Notice value is the aggregate market value the filer states they intend to sell — not a confirmed transaction. Compare to Insider Activity (Form 4) to see which planned sales actually executed. Market-wide feed: Planned sales (Form 144).
ETF Holders
121 ETFs hold PBH
25 shown · $695.75M total exposure · 0.13% AUM-weighted avg weight
| # | ETF | Provider | Weight | $ Exposure | ETF AUM | As Of |
|---|---|---|---|---|---|---|
| 1 | IJR iShares Core S&P Small-Cap ETF | iShares (BlackRock) | 0.13% | $139.1M | $101.9B | 2026-10-15 |
| 2 | VTI Vanguard Morningstar Total Stock Market ETF | Vanguard | 0.00% | $69.9M | — | 2026-09-30 |
| 3 | IWM iShares Russell 2000 ETF | iShares (BlackRock) | 0.08% | $60.9M | $75.2B | 2026-10-15 |
| 4 | VB Vanguard Morningstar Small-Cap ETF | Vanguard | 0.03% | $48.9M | — | 2026-09-30 |
| 5 | DFSV Dimensional US Small Cap Value ETF | Dimensional | 0.15% | $40.9M | — | 2026-10-15 |
| 6 | VXUS Vanguard Total International Stock ETF | Vanguard | 0.01% | $34.0M | — | 2026-09-30 |
| 7 | VBR Vanguard Morningstar Small-Cap Value ETF | Vanguard | 0.05% | $31.8M | — | 2026-09-30 |
| 8 | VXF Vanguard Extended Market ETF | Vanguard | 0.03% | $24.6M | — | 2026-09-30 |
| 9 | VEA Vanguard FTSE Developed Markets ETF | Vanguard | 0.01% | $22.6M | — | 2026-09-30 |
| 10 | IWN iShares Russell 2000 Value ETF | iShares (BlackRock) | 0.16% | $21.9M | $13.6B | 2026-10-15 |
| 11 | DFAT Dimensional US Targeted Value ETF | Dimensional | 0.07% | $21.7M | — | 2026-10-15 |
| 12 | SPSM State Street® SPDR® Portfolio S&P 600™ Small Cap ETF | SPDR (State Street) | 0.14% | $21.3M | $15.7B | 2026-10-15 |
| 13 | DFAS Dimensional US Small Cap ETF | Dimensional | 0.06% | $20.1M | — | 2026-10-15 |
| 14 | IJS iShares S&P Small-Cap 600 Value ETF | iShares (BlackRock) | 0.26% | $19.3M | $7.5B | 2026-10-15 |
| 15 | PJP Invesco Pharmaceuticals ETF | Invesco | 3.02% | $16.9M | — | 2026-10-15 |
| 16 | DFMC Dimensional US Micro Cap ETF | Dimensional | 0.19% | $14.0M | — | 2026-10-15 |
| 17 | VTWO Vanguard Russell 2000 ETF | Vanguard | 0.07% | $12.8M | — | 2026-09-30 |
| 18 | SLYV State Street® SPDR® S&P 600™ Small Cap Value ETF | SPDR (State Street) | 0.26% | $12.1M | $4.7B | 2026-10-15 |
| 19 | SCHA Schwab U.S. Small-Cap ETF | Nport | 0.05% | $10.8M | — | 2026-05-31 |
| 20 | CSMD Congress SMid Growth ETF | Nport | 2.21% | $9.6M | — | 2026-04-30 |
| 21 | XPH State Street® SPDR® S&P® Pharmaceuticals ETF | SPDR (State Street) | 2.07% | $9.3M | $451.1M | 2026-10-15 |
| 22 | DFAC Dimensional US Core Equity 2 ETF | Dimensional | 0.01% | $8.9M | — | 2026-10-15 |
| 23 | VSS Vanguard FTSE All-World EX-US Small-Cap Index Fund | Vanguard | 0.06% | $8.6M | — | 2026-09-30 |
| 24 | IHE iShares U.S. Pharmaceuticals ETF | iShares (BlackRock) | 0.52% | $8.0M | $1.5B | 2026-10-15 |
| 25 | VIOO Vanguard S&P Small-Cap 600 ETF | Vanguard | 0.13% | $7.7M | — | 2026-09-30 |
Fundamentals
Quarterly filings sourced from SEC 10-Q / 10-K reports. TTM tiles aggregate the most recent four quarters; bars show the last ~12 quarters oldest → newest.
Metrics
- Revenue — top-line sales. Look for consistent YoY growth; seasonal businesses need same-quarter comparisons (Q4 '24 vs Q4 '23).
- Net Income — bottom-line profit after all expenses. Can be volatile from one-time items; red bars = net loss.
- Diluted EPS — net income per share assuming options/converts are exercised. Direct input to the P/E ratio.
- Operating Cash Flow — cash generated from core operations, before capex and financing. Harder to manipulate than net income; growing OCF is a quality signal.
How to read the bars
- Sequential growth — quarter-over-quarter trend. Accelerating bars are a momentum signal.
- YoY growth — compare to the same quarter a year earlier to remove seasonality.
- Quality — OCF should roughly track Net Income over time. Large divergence (net income ≫ OCF) flags accruals risk.
- Margins — scan the bar ratios: Net Income / Revenue tells you margin trend without needing a separate chart.
TTM (trailing-twelve-month) smooths seasonality and is used for the P/E calculation. Filings appear 30–90 days after the period closes.
Trailing P/E
13.98
TTM Diluted EPS
$3.57
TTM Revenue
$1.10B
TTM Net Income
$172.01M
TTM Op. Cash Flow
$249.40M
Quarterly figures (12 quarters)
| Quarter | Period End | Revenue | Net Income | Diluted EPS | Op. Cash Flow |
|---|---|---|---|---|---|
| Q1 '27 | 2026-06-30 | $265.71M | $29.18M | $0.61 | $70.79M |
| Q4 '26 | 2026-03-31 | $281.62M | $53.93M | $1.13 | $42.84M |
| Q3 '26 | 2025-12-31 | $283.44M | $46.70M | $0.97 | $78.29M |
| Q2 '26 | 2025-09-30 | $274.11M | $42.21M | $0.86 | $57.49M |
| Q1 '26 | 2025-06-30 | $249.53M | $47.47M | $0.95 | $79.01M |
| Q4 '25 | 2025-03-31 | $296.52M | $50.13M | $1.01 | $61.85M |
| Q3 '25 | 2024-12-31 | $290.32M | $61.03M | $1.22 | $65.09M |
| Q2 '25 | 2024-09-30 | $283.79M | $54.38M | $1.09 | $69.80M |
| Q1 '25 | 2024-06-30 | $267.14M | $49.07M | $0.98 | $54.78M |
| Q4 '24 | 2024-03-31 | $276.99M | $49.46M | $0.98 | $66.91M |
| Q3 '24 | 2023-12-31 | $282.74M | $53.05M | $1.06 | $71.47M |
| Q2 '24 | 2023-09-30 | $286.32M | $53.56M | $1.07 | $62.46M |
Q1 2027 • period ending 2026-06-30 • filed 2026-08-06
Valuation
Ratios derived from TTM financials and the current market price, sampled daily. History chart shows how expensive the stock is today relative to its own recent past.
Price Multiples
- P/E — price / TTM earnings. Rough market rule: 10–15 value, 15–25 market, >30 growth/premium. Negative when earnings are negative.
- P/B — price / book value. Useful for financials and asset-heavy names; meaningless for asset-light software.
- P/S — price / TTM revenue. Useful when earnings are negative or noisy (early-stage growth).
- EV/EBITDA — capital-structure-neutral. <10 cheap, 10–15 reasonable, >20 rich. Good for comparing across leverage profiles.
- EV/Sales — like P/S but accounts for debt + cash. Compare within sector.
Profitability & Yields
- ROE — return on equity. >15% strong, >25% exceptional. Caution: high leverage inflates ROE.
- ROA — return on assets. Leverage-neutral; >5% solid, >10% exceptional.
- Div Yield — annual dividend / price. Compare to 10Y Treasury; sustained yield >6% often signals distress.
- FCF Yield — free cash flow / market cap. >5% is attractive; negative means burning cash.
Balance Sheet
- Debt/Equity — leverage. <1 conservative, >2 aggressive. Sector-dependent (utilities naturally high, tech low).
- Current Ratio — short-term liquidity. >1.5 comfortable, <1 raises short-term solvency flags.
Reading the history chart
- Compare current level to the 3-year band: near the high end = relatively expensive; near the low = relatively cheap.
- Multiples expanding while earnings are flat = sentiment-driven rally.
- Multiples compressing while earnings grow = value coming from fundamentals.
P/E
13.98
P/B
1.26
P/S
2.19
EV/EBITDA
13.49
EV/Sales
3.94
ROE
9.0%
ROA
3.8%
Div Yield
0.00%
FCF Yield
10.32%
Debt/Equity
1.06
Current Ratio
—
Market Cap
$2.42B
as of 2026-10-16
Short Interest & Float
Regulatory short-interest reports publish on a bi-weekly settlement cadence; short-volume is reported daily by the trade-reporting facilities. Float is derived from insider-ownership filings.
Metric definitions
- Short Interest — total shares currently sold short as of the settlement date. Lags real time by ~8 business days.
- SI % of Float — short interest / free float. The key crowding metric.
- Days to Cover — short interest / avg daily volume. How many full trading days it would take shorts to buy back. High DTC + catalyst = squeeze fuel.
- Short Vol Ratio — today's short-sale volume / total volume. Intraday selling pressure proxy (not the same as short interest).
- Free Float — shares available for public trading (total shares minus insider / restricted).
- Float % — free float / shares outstanding. <50% = tightly held, more prone to squeezes.
How to read the signals
- SI % of Float < 5% — typical, no particular signal.
- 5–15% — elevated; watch for catalysts (earnings, guidance, macro).
- 15–30% — heavily shorted; tight-float names in this range have produced notable squeezes historically.
- >30% — extreme; borrow is likely expensive and squeeze risk is material.
- Days to Cover > 5 combined with high SI% amplifies squeeze potential.
History chart
- Trend matters more than level. Rapidly rising short interest often precedes negative catalysts or heavy hedging.
- A sudden drop in SI after a rally may indicate a squeeze in progress.
Short interest is reported mid-month and end-of-month; short volume is daily.
Short Interest
4.64M
SI % of Float
9.96%
Days to Cover
6.60
Short Vol Ratio
51.5%
Free Float
46.64M
Float %
98.5%
Short interest 2026-09-30 • Short volume 2026-10-16 • Float 2026-08-24